JP2018528261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528261A5 JP2018528261A5 JP2018525526A JP2018525526A JP2018528261A5 JP 2018528261 A5 JP2018528261 A5 JP 2018528261A5 JP 2018525526 A JP2018525526 A JP 2018525526A JP 2018525526 A JP2018525526 A JP 2018525526A JP 2018528261 A5 JP2018528261 A5 JP 2018528261A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- group
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 1
- -1 N-substituted amino Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
Claims (15)
- 式(I)を有する化合物、またはその薬学的に許容可能な塩:
式中:
Xは、−(CH2)n−であり、nは、1、2、3、4、5、6、7、および8からなる群より選択される整数であり;
R1は、H、C1-6直鎖アルキル、置換C1-6直鎖アルキル、C1-6分岐アルキル、および置換C1-6分岐アルキルからなる群より選択され;
R2は、アミノ酸、N-置換アミノ酸、および-C(=O)-O-(CR3R4)m-O-C(=O)-R10からなる群より選択され;
R2'は、H、C1-C6アルキル、および置換C1-C6アルキルからなる群より選択され;
各R3およびR4は独立して、H、C1-C6アルキル、置換C1-C6アルキル、アリール、置換アリール、-(CR3R4)m-NR5R6、または
であり;
mは、1、2、3、4、5、6、7、および8からなる群より選択される整数であり;
R5およびR6は独立して、Hまたはアルキルであり;
R10は、アルキル、置換アルキル、シクロアルキル、置換シクロアルキル、単糖、アシル化単糖、アリール、置換アリール、ヘテロアリール、および置換ヘテロアリールからなる群より選択される。 - Xが-CH2-である、請求項1記載の化合物。
- R1が、メチル、エチル、およびイソプロピルからなる群より選択される、請求項1記載の化合物。
- R2が、-C(=O)-Y-(CR3R4)m-NR5R6、および-C(=O)-O-(CR3R4)m-O-C(=O)-R10からなる群より選択され;
式中、
Yは、−O−または結合であり;
mは、0、1、2、3、4、5、6、7、および8からなる群より選択される整数であり;
各R3およびR4は独立して、H、C1-C6アルキルもしくは置換C1-C6アルキル、アリールもしくは置換アリールであり;
R10は、アルキル、置換アルキル、シクロアルキル、置換シクロアルキル、アリール、置換アリール、ヘテロアリール、または置換ヘテロアリールであある、
請求項1記載の化合物。 - R2が、-C(=O)-Y-(CR3R4)m-NR5R6であり;
式中、
Yは結合であり;
mは1であり;
R5およびR6はそれぞれHである、
請求項4記載の化合物。 - R2がアミノ酸である、請求項1記載の化合物。
- R2がN-アシルアミノ酸である、請求項1記載の化合物。
- アミノ酸がトリプトファンである、請求項6または7記載の化合物。
- R2が-C(=O)-O-(CR3R4)m-O-C(=O)-R10であり;
式中、
(i) mは1であり;
R3はHであり;かつ
R4は、メチル、iPr、もしくはアリールであるか;
(ii) mは1であり;
R3およびR4はそれぞれHであるか;または
(iii)mは1であり;
R3およびR4はそれぞれメチルである、
請求項4記載の化合物。 - 請求項1〜13のいずれか一項記載の化合物、またはその薬学的に許容可能な塩と、薬学的に許容可能な担体、希釈剤、または賦形剤とを含む、医薬組成物。
- 請求項1〜13のいずれか一項記載の化合物またはその薬学的に許容可能な塩と、薬学的に許容可能な担体、希釈剤、または賦形剤とを含む、対象におけるがんを治療するのに用いられる医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562199566P | 2015-07-31 | 2015-07-31 | |
US62/199,566 | 2015-07-31 | ||
PCT/US2016/044767 WO2017023774A1 (en) | 2015-07-31 | 2016-07-29 | Prodrugs of glutamine analogs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018528261A JP2018528261A (ja) | 2018-09-27 |
JP2018528261A5 true JP2018528261A5 (ja) | 2019-09-05 |
JP6863981B2 JP6863981B2 (ja) | 2021-04-21 |
Family
ID=57943518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018525526A Active JP6863981B2 (ja) | 2015-07-31 | 2016-07-29 | グルタミン類似体のプロドラッグ |
Country Status (21)
Country | Link |
---|---|
US (4) | US10336778B2 (ja) |
EP (1) | EP3328827B1 (ja) |
JP (1) | JP6863981B2 (ja) |
CN (2) | CN108290827B (ja) |
AU (1) | AU2016302940B2 (ja) |
CA (1) | CA2994258A1 (ja) |
DK (1) | DK3328827T3 (ja) |
EA (1) | EA034571B1 (ja) |
ES (1) | ES2957583T3 (ja) |
FI (1) | FI3328827T3 (ja) |
HK (1) | HK1256284A1 (ja) |
HR (1) | HRP20231163T1 (ja) |
HU (1) | HUE063399T2 (ja) |
IL (1) | IL257219B (ja) |
LT (1) | LT3328827T (ja) |
MX (1) | MX2018001300A (ja) |
PL (1) | PL3328827T3 (ja) |
PT (1) | PT3328827T (ja) |
RS (1) | RS64597B1 (ja) |
SI (1) | SI3328827T1 (ja) |
WO (1) | WO2017023774A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10842763B2 (en) | 2015-07-31 | 2020-11-24 | The Johns Hopkins University | Methods for cancer and immunotherapy using prodrugs of glutamine analogs |
WO2017023787A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Methods and compositions for treating metabolic reprogramming disorders |
WO2017023774A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Prodrugs of glutamine analogs |
CA2994162A1 (en) * | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Glutamine antagonists for the treatment of cognitive deficits |
EP3576727A4 (en) | 2017-02-01 | 2020-09-09 | The Johns Hopkins University | GLUTAMINE ANALOGUES MEDICINAL PRODUCTS |
CN111566083A (zh) * | 2017-10-06 | 2020-08-21 | 约翰·霍普金斯大学 | 新的谷氨酰胺拮抗剂及其用途 |
EP3911310A4 (en) * | 2019-01-18 | 2022-10-12 | Dracen Pharmaceuticals, Inc. | COMBINATION THERAPY WITH A DON-PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR |
EP3924330A4 (en) * | 2019-02-11 | 2022-11-09 | Dracen Pharmaceuticals, Inc. | PROCESS FOR THE PREPARATION OF A DON-PRODRUGE FROM L-GLUTAMIC ACID |
KR20210151056A (ko) * | 2019-02-11 | 2021-12-13 | 드라센 파마슈티컬스, 인코포레이티드 | L-피로글루탐산으로부터 don 전구약물을 제조하는 방법 |
US20220332676A1 (en) * | 2019-10-03 | 2022-10-20 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof |
CN110763792A (zh) * | 2019-10-24 | 2020-02-07 | 湖北省宏源药业科技股份有限公司 | 一种鸟嘌呤有关物质检测方法 |
WO2021239049A1 (en) * | 2020-05-27 | 2021-12-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
EP4221842A1 (en) * | 2020-10-02 | 2023-08-09 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
JP2023546100A (ja) * | 2020-10-15 | 2023-11-01 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッド | 新規グルタミン類似体 |
WO2022078462A1 (en) * | 2020-10-15 | 2022-04-21 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
CN114621120B (zh) * | 2020-12-10 | 2023-11-03 | 深圳先进技术研究院 | 一种don前药分子、前药激活化合物和前药激活体系 |
WO2022232565A1 (en) * | 2021-04-29 | 2022-11-03 | The Johns Hopkins University | Prodrugs of 6-diazo-5-oxo-l-norleucine |
WO2022261117A1 (en) * | 2021-06-07 | 2022-12-15 | Dracen Pharmaceuticals, Inc. | Combination therapy with a don prodrug and a tigit inhibitor |
CN113461563B (zh) * | 2021-07-27 | 2022-05-10 | 中国药科大学 | Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用 |
CN114306620A (zh) * | 2021-12-07 | 2022-04-12 | 深圳先进技术研究院 | 基于代谢检查点的人血清白蛋白纳米药物及其制备方法和应用 |
WO2023145880A1 (ja) * | 2022-01-28 | 2023-08-03 | 国立大学法人富山大学 | グルタミナーゼ阻害剤 |
CN114917230B (zh) * | 2022-03-09 | 2023-03-24 | 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) | Cb-839在制备抑制角膜新生血管生成的药物中的应用 |
TW202406539A (zh) * | 2022-04-21 | 2024-02-16 | 大陸商北京加科思新藥研發有限公司 | 藥物組合及其用途 |
TW202404938A (zh) * | 2022-04-21 | 2024-02-01 | 大陸商北京加科思新藥研發有限公司 | 麩醯胺酸拮抗劑的多晶型及其用途 |
CN114805138B (zh) * | 2022-05-12 | 2023-10-10 | 中国科学院长春应用化学研究所 | 6-重氮-5-氧代-l-正亮氨酸的前药、其制备方法及应用 |
WO2024094526A1 (en) | 2022-11-02 | 2024-05-10 | Ecole Polytechnique Federale De Lausanne (Epfl) | 6-diazo-5-oxo-l-norleucine prodrugs |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US121179A (en) * | 1871-11-21 | Improvement in brick-kilns | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4503044A (en) * | 1983-04-25 | 1985-03-05 | American Cyanamid Company | Antibiotic LL-D05139 β |
US4568646A (en) * | 1983-04-25 | 1986-02-04 | American Cyanamid Company | Preparation of antibiotic LL-D05139β from cultures of Glycomyces harbinensis, gen. nov., sp. nov. |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
TR199802049T2 (xx) * | 1996-04-12 | 1999-01-18 | G.D.Searle & Co. | COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri. |
AU4517201A (en) | 1999-12-08 | 2001-06-18 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
CA2423313A1 (en) | 2000-09-29 | 2002-04-04 | Z. Robert Zhong | Methods of treating inflammatory and immune reactions and compositions therefor |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1507549A4 (en) | 2002-05-14 | 2009-07-01 | Univ Leland Stanford Junior | MEDICAMENT THERAPY AGAINST CELIAC SPRUE |
AU2003294221A1 (en) * | 2002-09-13 | 2004-04-19 | Kenneth E. Miller | Method of alleviating pain via inhibition of neurotransmitter synthesis |
GB0314262D0 (en) * | 2003-06-19 | 2003-07-23 | Univ Nottingham Trent | Novel compounds and methods of using the same |
US7109239B2 (en) | 2003-08-20 | 2006-09-19 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
US7579313B2 (en) | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
AU2005205182B2 (en) | 2004-01-19 | 2009-07-16 | Novartis Ag | Indolylmaleimide derivatives |
EP1734952A1 (en) | 2004-04-08 | 2006-12-27 | Novartis AG | Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection |
WO2007001395A2 (en) | 2004-10-04 | 2007-01-04 | University Of South Carolina | Prevention and treatment of influenza with glutamine antagonist agents |
US7976852B2 (en) | 2005-04-26 | 2011-07-12 | Eisai R&D Management Co., Ltd. | Compositions and methods for cancer immunotherapy |
JP2009529047A (ja) | 2006-03-07 | 2009-08-13 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環系ピラゾール化合物およびその使用 |
US8465736B2 (en) | 2006-05-10 | 2013-06-18 | New Medical Enzymes Ag | Glutadon |
WO2008033572A1 (en) | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
US20080107623A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US20080160024A1 (en) | 2006-12-07 | 2008-07-03 | Board Of Trustees Of The University Of Arkansas | Inhibition of cancer metastasis |
WO2009029729A1 (en) | 2007-08-31 | 2009-03-05 | Genelabs Technologies, Inc. | Amino tricyclic-nucleoside compounds, compositions, and methods of use |
US8580312B2 (en) | 2010-02-17 | 2013-11-12 | National University Corporation Kobe University | Radiation therapy agent |
US8592427B2 (en) | 2010-06-24 | 2013-11-26 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
EP2686020B1 (en) | 2011-03-17 | 2017-02-22 | The University of Birmingham | Re-directed immunotherapy |
KR101900478B1 (ko) | 2011-08-04 | 2018-09-20 | 한올바이오파마주식회사 | 암의 재발 또는 전이의 억제용 약제학적 조성물 |
WO2014138391A1 (en) * | 2013-03-06 | 2014-09-12 | The Johns Hopkins University | Targeting glutamine metabolism in brain tumors |
US20160022708A1 (en) | 2013-03-14 | 2016-01-28 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of glutamine-addicted cancers |
US10966998B2 (en) | 2013-09-05 | 2021-04-06 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
JP2016540042A (ja) | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ, インコーポレイテッド | がんを処置するためのチェックポイント阻害剤および治療薬の組合せ |
WO2015089114A1 (en) * | 2013-12-09 | 2015-06-18 | Bullet Biotechnology, Inc. | Specific virus-like particle-cpg oligonucleotide vaccines and uses thereof |
JP6666263B2 (ja) | 2014-01-06 | 2020-03-13 | ライゼン・ファーマシューティカルズ・エスアー | グルタミナーゼの新規阻害剤 |
WO2015138902A1 (en) | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
CN107027291B (zh) | 2014-06-13 | 2020-10-30 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂的组合疗法 |
WO2016172494A2 (en) | 2015-04-23 | 2016-10-27 | The Johns Hopkins University | Combination of immunotherapy with local chemotherapy for the treatment of malignancies |
CA2994162A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Glutamine antagonists for the treatment of cognitive deficits |
WO2017023774A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Prodrugs of glutamine analogs |
WO2017023787A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Methods and compositions for treating metabolic reprogramming disorders |
US10842763B2 (en) | 2015-07-31 | 2020-11-24 | The Johns Hopkins University | Methods for cancer and immunotherapy using prodrugs of glutamine analogs |
-
2016
- 2016-07-29 WO PCT/US2016/044767 patent/WO2017023774A1/en active Application Filing
- 2016-07-29 LT LTEPPCT/US2016/044767T patent/LT3328827T/lt unknown
- 2016-07-29 PT PT168336238T patent/PT3328827T/pt unknown
- 2016-07-29 CN CN201680057659.8A patent/CN108290827B/zh active Active
- 2016-07-29 SI SI201631748T patent/SI3328827T1/sl unknown
- 2016-07-29 HR HRP20231163TT patent/HRP20231163T1/hr unknown
- 2016-07-29 HU HUE16833623A patent/HUE063399T2/hu unknown
- 2016-07-29 EA EA201890395A patent/EA034571B1/ru unknown
- 2016-07-29 CN CN202011474256.8A patent/CN112920092B/zh active Active
- 2016-07-29 DK DK16833623.8T patent/DK3328827T3/da active
- 2016-07-29 PL PL16833623.8T patent/PL3328827T3/pl unknown
- 2016-07-29 EP EP16833623.8A patent/EP3328827B1/en active Active
- 2016-07-29 CA CA2994258A patent/CA2994258A1/en active Pending
- 2016-07-29 ES ES16833623T patent/ES2957583T3/es active Active
- 2016-07-29 MX MX2018001300A patent/MX2018001300A/es unknown
- 2016-07-29 JP JP2018525526A patent/JP6863981B2/ja active Active
- 2016-07-29 RS RS20230850A patent/RS64597B1/sr unknown
- 2016-07-29 FI FIEP16833623.8T patent/FI3328827T3/fi active
- 2016-07-29 AU AU2016302940A patent/AU2016302940B2/en active Active
-
2018
- 2018-01-29 IL IL257219A patent/IL257219B/en active IP Right Grant
- 2018-01-31 US US15/885,258 patent/US10336778B2/en active Active
- 2018-11-30 HK HK18115348.7A patent/HK1256284A1/zh unknown
-
2019
- 2019-06-27 US US16/454,880 patent/US10738066B2/en active Active
- 2019-06-27 US US16/454,853 patent/US10954257B2/en active Active
-
2021
- 2021-03-19 US US17/207,388 patent/US11926640B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018528261A5 (ja) | ||
JP2011219498A5 (ja) | ||
JP2020169171A5 (ja) | ||
JP2019512478A5 (ja) | ||
JP2018507890A5 (ja) | ||
JP2015522650A5 (ja) | ||
JP2014503574A5 (ja) | ||
JP2016053042A5 (ja) | ||
RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
JP2016505586A5 (ja) | ||
JP2014503567A5 (ja) | ||
JP2017509586A5 (ja) | ||
JP2014532716A5 (ja) | ||
JP2010527913A5 (ja) | ||
JP2008510828A5 (ja) | ||
JP2008509166A5 (ja) | ||
JP2006515858A5 (ja) | ||
JP2019524883A5 (ja) | ||
JP2017511321A5 (ja) | ||
RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
RU2016135922A (ru) | Терапевтические соединения и композиции | |
JP2010511721A5 (ja) | ||
JP2019500387A5 (ja) | ||
JP2015504076A5 (ja) | ||
RU2006146215A (ru) | Производные аминопропанола |